Article
Life Sciences Quarterly Q3 2026
Q3 2026 brought significant legal and regulatory developments for the life sciences sector in Norway and the EU. This quarterly update examines key changes including enhanced transparency in Norwegian market access decisions, proposed implementation of the EU's SoHO Regulation expanding regulatory frameworks for substances of human origin, and major EU pharmaceutical reforms including the adoption of the EU Pharma Package.
BAHR